Health

Fulfill Unmet Medical Needs (Priority Issue 1)

Targets for FY2030	Major activities of FY2022	Self- evalution
Develop and disseminate new treatments based on regenerative medicine and cell therapy	Set up our first BIO CDMO site in Toyama to expand business in the Asian markets and strengthen the vaccine production system in Japan (Plan to start its operation in 2027) Decided to make a new large-scale investment totaling approximately 200 billion yen in its U.S. and European bases to accelerate growth of its contract biopharmaceutical development and manufacturing business Established a local subsidiary in South Korea to accelerate business growth of cell culture media Issued a 120 billion yen social bond, Japan's largest ever in terms of financing for a Bio CDMO business. The bond won the Grand Prize, the highest award, at the 8th Sustainable Finance Awards	〇

Learn more

Improve Accessibilities to Medical Services (Priority Issue 2)

Targets for FY2030	Major activities of FY2022	Self- evalution
(1) Reducing burden on medical professionals by utilizing IT	Launched joint research with Tokyo Metropolitan Institute of Gerontology and Geriatric Medicine on a dementia screening test method using AI technology. Launched the “SYNAPSE VINCENT Cloud” service, providing 3D image analysis system “SYNAPSE VINCENT” applications in the cloud Launched eScreening, a support function for breast ultrasound examinations. Created new NURA centers, health checkup centers focused chiefly on cancer, in India (Gurugram and Mumbai) Promoted to tackle with tuberculosis control initiatives in developing countries Introduced our AI-driven products and services to 93 countries/regions	〇
(2) Development and dissemination of infectious disease diagnostic system to contribute to global health
(3) Offering technical diagnosis training and spreading effective health practices to emerging countries
(4) Improve medical accessibility by introducing our AI-driven products/services to all 196 countries/regions

Learn more

Efforts to End Tuberculosis

Contribute to Early Disease Detection (Priority Issue 3)

Targets for FY2030	Major activities of FY2022	Self- evalution
Reduce the physical burden through widespread and expanded use of medical diagnostic systems	Created new NURA centers, health checkup centers focused chiefly on cancer, in India (Gurugram and Mumbai) Promoted to tackle with tuberculosis control initiatives in developing countries Launched AMULET ELITE, a compact digital mammography system for breast clinics and checkup buses Launched FUJI Drychem IMMUNO AG Cartridge COVID-19/Flu, a simultaneous COVID-19 and influenza test kit based on highly sensitive detection technology using silver halide amplification reaction	〇

Efforts to End Tuberculosis

Contribute to Health Promotion and Beauty (Priority Issue 4)

Targets for FY2030	Major activities of FY2022	Self- evalution
(1) Promote to prolong healthy lives	Launched AYUMATE, a new functional food product that reduces discomfort in knee joints when moving such as walking and climbing stairs Launched ASTALIFT THE SERUM, a series of highly functional serums based on proprietary liposome technology, a medicated multifunctional serum, and a medicated wrinkle-improving serum	〇
(2) Promote support for women’s empowerment		〇

Promote Management of a Healthy Workplace (Priority Issue 5)

Targets for FY2030	Major activities of FY2022	Self- evalution
Promote management of health and productivity to maintain employees’ vitality	Opened FUJIFILM Mediterrace Yokohama as a health checkup facility for employees, as part of our health and productivity management Selected for the Health and Productivity Stock Selection Program for third consecutive year Health Management e-Learning “Recommendations for Gastric and Colorectal Cancer Screening” for Fujifilm Group employees in Japan	〇

Data and Information：Health, Safety and Wellness of Employees

PDF：4.48MB

Learn more

Future Activities and Targets

We will continue to make capital investments in our bio-CDMO and life science businesses and provide one-stop value as a company that supports the creation of cutting-edge biopharmaceuticals.

In the medical systems business, we will continue to develop and provide a variety of products and services that meet the needs of the medical field and contribute to the development of medical care worldwide and the maintenance and improvement of people's health by positioning medical IT at the core of our business and linking each product group based on medical imaging, picture archiving and communication systems (PACS). We will also contribute to solving the issue of eliminating medical disparities through our unique solutions, such as NURA, a health checkup service business in India, and tuberculosis screening using portable X-ray equipment.

Furthermore, in promoting health management, we will accelerate efforts to maintain and improve the health of employees throughout the Group in the five priority areas (lifestyle-related diseases, smoking, cancer, mental health, and long working hours), and to achieve our mid-term goal by FY2025, thereby contributing to the realization of a healthy society with longevity.